
‘I have vaginismus and I'm afraid I'll never find a man who doesn't pressure me'
I am a straight woman in my late 20s, and I have diagnosed vaginismus. I have attended a few initial sessions with a qualified sex therapist, but have not gone as far as using dilators. I have tried and failed to have penetrative sex in the past, with men I was not in a committed relationship with, and have not been successful. I now have a better relationship with my body, having explored other paths to sexual satisfaction such as using vibrators, and am easily able to reach orgasm. But I still haven't been in a heterosexual relationship, and part of the reason is vaginismus. The partners with whom
I attempted penetrative sex
in college backed away once it became clear that sex was not straightforward.
I am willing to have a mature conversation about my condition with a man I am dating if it looks like things are becoming serious, but I then feel a pressure to quickly train using the dilators purely because the man may have penetrative sex high on his list of crucial relationship markers, and this frustrates me. I need a partner with patience and understanding. I want to train on dilators for my own pleasure, but back away every time, partially because I feel I'm really only doing it to serve men's pleasure. I'm open-minded and would love your thoughts.
Thank you for writing. What you've described is more common than most people realise, but because vaginismus is so rarely talked about openly, many women carry it quietly and with shame. Your self-awareness, reflection and act of sharing your experience here are already powerful acts of courage, so be proud of yourself – just by addressing this issue, you're making life less lonely for others going through the same experience.
READ MORE
Clinically, vaginismus is described as an involuntary spasm of the vaginal muscles when penetration is attempted. That's not wrong, but it's incomplete. This framing it puts all the focus on the vaginal muscle, as if that's the only part of your body that matters. But vaginismus is more than a muscle reflex – it's a whole-body, whole-person experience, and it often involves fear, pain, anticipation, and deep emotional responses that are shaped by personal history, relationships, and social messaging around sex.
There are different types of vaginismus. Primary vaginismus is when a woman has never been able to tolerate vaginal penetration – not just sex, but things like tampons or gynaecological exams. For many women, it's not just discomfort; it's physically impossible.
Then there's secondary vaginismus, where a woman has previously been able to experience penetration, but then experiences a change like a painful medical experience, a trauma, an injury, or even just one unexpectedly painful encounter that triggered a protective tightening of the muscles going forward. The body, trying to shield itself from more pain, responds by closing off.
Both types of vaginismus are real, both are valid, and neither define your worth or your ability to have a full, intimate, loving life.
.form-group {width:100% !important;}
Some women who experience vaginismus have been deeply impacted by the cultural messaging they've experienced around sex. If you have been taught that penetrative sex is dangerous in some way – socially, emotionally or psychologically – it makes sense that the body would try to protect itself from it. And if your experience does resonate with vaginismus even without a formal exam, you deserve to be believed and supported. Some women have unfortunately reported having insensitive and upsetting interactions with doctors who either patronise them, pathologise them, or insist on invasive examinations, and this should never be the norm or tolerated. You know your body, and you deserve support.
[
'I got back with my partner after breaking up with him but I am still plagued by doubts'
Opens in new window
]
I know you know this on some level. What I hear in your letter is a woman who's caught in the tension between healing on her own terms and feeling pressure to make that healing palatable or convenient for potential partners. That's a hard place to be, especially in a culture that puts penetrative sex on a pedestal. It's great that you've taken the important step of seeing a qualified sex therapist, which shows commitment to healing. But remember to give yourself a lot of patience and grace. The early stages of therapy can be disorienting. You may not yet feel ready to begin physical tools like dilators, and that's okay. Therapy is not a race, and it's certainly not about 'fixing' you. It's about understanding yourself with more compassion and care.
What's also wonderful is that you've found your own path to pleasure through solo exploration – which
is
sex! Masturbation, non-penetrative touching, orgasms – all of this is sex, and counts as sex when done with a partner too – as does oral sex, using sex toys and all the other things sex can entail apart from penile-vaginal penetration. Many women don't even orgasm from penetration, yet it's still held up as the ultimate goal – which is ridiculous and limiting. There's a whole world of sexual intimacy beyond penetration, and good partners – the ones worth your time – will understand that. They won't rush you or see vaginismus as a barrier to intimacy, because they'll know there are many ways to connect.
You seem unsure that kind of partner exists. There's an urgency and pressure in your letter, driven by fear of not being accepted by a future partner who isn't even here yet. So it makes perfect sense that your body is hesitant. If you're using dilators just to make yourself more 'acceptable,' your body will resist – and rightly so. That's not failure; it's self-protection.
Try shifting your focus. Instead of centring what a potential partner might want from you sexually, centre what you want in a partner generally. If dating feels daunting, that's understandable – especially if your past partners lacked empathy or put pressure on you. These past experiences deserve exploration and empathy in therapy. But it's also important to remember that not all men are like that. Enter dating expecting kindness, emotional intelligence, and respect as the baseline. Think of dating exploration and connection. Move slowly. Be discerning. Maintain boundaries. Notice who makes you feel safe, and comfortable, and like yourself. Assume you deserve to be treated well – and don't accept less.
You might also find it helpful to connect with online vaginismus communities. They can reduce isolation, offer support, and show you what's possible. Many women with vaginismus are in loving, thriving relationships with supportive partners. For couples navigating this together, sex-positive couples therapy can be transformative. Seeing these stories may ease the pressure you're putting on yourself and help dismantle the belief that men will inevitably pressure you into penetrative sex – which, frankly, is the type of man no woman should be dating anyway.
If you decide to have that conversation with a future partner, you're not revealing a flaw – you're sharing an important part of your story. The right person will see that as a strength. You get to say: 'Here's what I've learned about my body. Here's what I enjoy. Here's what I'm still working on.' And then you get to watch how they respond. That response will tell you a lot. If you share your story with someone and they back away, that's not a reflection of your worth. That's a filter.
[
'My ex blanks me at group events – and my family and friends make excuses for him'
Opens in new window
]
Whatever comes next – whether it's more therapy, dilators, dating, or just continuing to enjoy solo pleasure – know this: you are already doing the work. You're already enough. Your body deserves respect, and so do you. Give it yourself, and expect it from others. Wishing you the best of luck.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Irish Times
3 days ago
- Irish Times
Gareth Sheridan: Nutriband ‘will help a lot of people who are dealing with addiction and people who are dealing with pain'
Nutriband is a pharmaceutical company that was founded in Dublin in 2012 before relocating to Florida in 2016. Gareth Sheridan, who recently announced his intention to run for president and has stepped aside for three months as chief executive, is its founder. The company's lead product is Aversa, which it describes as 'abuse-deterrent transdermal technology', which incorporates aversive agents to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential, specifically opioids. Its first application is its abuse-deterrent fentanyl transdermal patch, which it is developing to provide clinicians and patients with extended-release chronic pain relief. It is awaiting regulatory clearance for this product in the US. The company has operations in Florida, Georgia, and North Carolina, and recently began its expansion back to Dublin. READ MORE What lightbulb moment prompted you to start-up in business? It was originally a thesis idea. I had noticed a patch that my dad wears and began wondering what other types of medications could be delivered that way that had not been explored yet. The thesis became a business plan, and Nutriband was registered in 2012. Describe your business model and what makes your business unique. We structured the company in a unique way, using capital markets and a public listing approach. We listed on the OTC Markets in 2016 and started using stock to purchase companies and technologies in place of cash. This helped us to avoid raising expensive early capital and retain a major equity stake in the company today, even after an eventual qualification to list on the Nasdaq (in New York) in 2010. We also do not develop new drug applications. We take existing generic medications and use our technologies to improve upon those and relaunch them as a branded product again. What is your greatest business achievement to date? Growing the company to a level where we qualified to list on the Nasdaq Stock Exchange and getting to ring the opening bell. What was your back-to-the-wall moment and how did you overcome it? We almost got sued by the SEC (The US Securities and Exchange Commission) for an accidental erroneous disclosure in one of our filings while on the OTC markets. At first, we thought it could be explained. However, it grew to the point where they were doubling down. We hired an excellent attorney with SEC experience and eventually settled the issue in a cease-and-desist, no-admit, no-deny agreement. This led to our back-to-the-wall moment, where, while running on fumes financially, we received a rejection from Nasdaq in our first application. After a couple of days of self-pity, we got back to work, raised some working capital with existing shareholders, and grew the company's equity by $7.5 million (€6.4 million) over the course of the next year. We reapplied to list again successfully. What moment would you cite as a turning point for the company? Credibility provided by our Nasdaq listing and subsequent partnership with Kindeva Drug Delivery (formerly 3M Drug Delivery), where Kindeva supplied their generic approved fentanyl patch for us to add our technology to. What were the best and the worst pieces of advice you received when starting out? The worst advice was that banks and institutions have your company's best interests at heart. I firmly believe that today, Wall Street is built on companies failing, not succeeding. Describe your growth funding path. We were reluctant to raise expensive capital early on and instead listed the company to use stock as an acquisition currency to grow. Our gamble on this paid off, and although we raised modest cash along the way, we were able to build Nutriband without any significant seed or angel rounds. We reached a market capitalisation of $120 million (its market value currently is about $75 million), and we have been able to maintain stable and steady control as a result of the minimal capital rounds. We turn down anywhere from $5 million to $15 million on a weekly basis from funds and institutions because we do not need it. We are not in the business of raising money, and having as little dilution as possible is a core focus for us as a company. How will your market look in three years and where would you like your business to be? For our first product, we are expected to reach annual revenues of $200 million. Our second product is independently estimated to have upwards of $135 million in yearly revenue. We are targeting the billion dollar club before the end of 2027. What are your annual revenues and profits? We are not yet profitable, as is typical with clinical development-stage companies. However, we also contract manufacture sports tapes and products for brands such as Reebok and KT Tape. Our target revenue from this source for the financial year to the end of January 2026 is $3 million * . This goes towards operational costs and reduces our clinical burn. Why have you decided to seek a nomination for the presidency? It's never been a more important or relevant time in our history for a young president, particularly with the average age just under 40. I would be hoping that having a younger president would help narrow the division we're seeing in the country at the moment and that we can work together to tackle the issues, particularly the housing crisis. The younger generation aren't feeling very enthusiastic that their voices are being heard. What impact will this move have on your business? The company is in very safe hands and the biggest asset at the company is the team. We've got a very definite plan and timeline between now and Christmas on what needs to be achieved. Whether I'm in there or not that timeline needs to be adhered to. The company is motoring along fine. Stepping aside is not something that I think will fundamentally affect the opportunity for the company. What happens if you win? There are mechanisms where I can put the shares into a trust. I would be very proud that it was a company that I started and be very keen to still follow the journey, just not as CEO. Nutriband as a whole is going to do a lot of will help a lot of people who are dealing with addiction and people who are dealing with pain. *An earlier version of this article stated a higher target figure for contract manufacturing, which has since been revised by the company.


Irish Times
6 days ago
- Irish Times
Dementia and AI: ‘I've never seen something quite like this'
When Frank Poulsen first started talking to artificial intelligence companion Sunny earlier this year, she was 'kind of formal,' he said. But over time, their conversations have become more familiar and engaging. 'It's really uncanny,' said the 72-year-old. 'It really does feel like you're having a conversation with someone who's interested.' One advantage of Sunny is that she doesn't mind when Poulsen, who was diagnosed with mild cognitive impairment in 2019, repeats himself. 'He can tell a story and forget he told it and tell it again,' said Poulsen's wife and caregiver, Cheryl Poulsen. 'Sunny has no judgment.' Sunny, which was developed by AI start-up NewDays, is part of a rapidly expanding body of AI products designed to help people with dementia . READ MORE 'I've never seen something quite like this in terms of a technology moving as quickly as it is, with as much money poured behind it,' said Luke Stoeckel, a programme director and project scientist at the National Institute on Aging in Maryland, in the United States, who works on AI applications for dementia care. Stoeckel mentioned AI-based dementia diagnostics as another hot area. Experts say AI companions like Sunny have the potential to help keep the brain active and alleviate loneliness in dementia patients, and to reduce some of the burden on caregivers. But there can be risks when it comes to deploying this technology in such a vulnerable population. Babak Parviz, the co-founder and CEO of NewDays, said he was inspired to develop Sunny in part by his own father's diagnosis with Alzheimer's disease. He knew there was no cure, but he was encouraged by research showing that cognitive training exercises and guided conversations with a clinician can, in some cases, improve dementia symptoms. NewDays' program is intended to be used by people with mild cognitive impairment or mild dementia. Sometimes, Sunny prompts the person to reminisce about old memories. Other times, it leads them through more explicit cognitive training exercises, such as asking them to remember and use specific words in a sentence. When Frank Poulsen opens up his computer and converses with Sunny, it sounds like 'he was just having a chat, like he was talking to a friend,' Cheryl Poulsen said. NewDays' website claims that its program can 'delay decline and improve quality of life' and that it is 'backed by a large body of evidence from more than 500 clinical trials and papers.' That includes the I-CONECT study, which found that, over the course of six months, 'cognitively stimulating semistructured conversations with trained interviewers' conducted virtually improved cognition in older adults with mild cognitive impairment. [ 'Dementia is just one part of who they are. My husband's underlying personality hasn't really changed' Opens in new window ] But in those studies, the conversations and brain training exercises were led by humans, said Julian De Freitas, director of the Ethical Intelligence Lab at Harvard Business School. Talking to an AI companion could produce different results, he added. NewDays has not run any studies yet about whether using its program confers the same benefits. Dr Parviz said Sunny's conversations are similar to a human's and that his team is 'pretty confident' it will see results comparable to what the existing clinical trials have demonstrated. But he did not provide data to back that up. There is more compelling evidence that an AI companion can help people feel less lonely – a serious concern for older adults, whether or not they have cognitive impairment. Dr De Freitas's own research has demonstrated that, at least in healthy adults, talking to an empathetic chatbot is roughly as good at reducing loneliness as having a conversation with a human stranger. Anecdotally, Dr Joe Verghese, the chair of the neurology department at Stony Brook University Renaissance School of Medicine, said the caregivers of some of his dementia patients reported that talking to an AI companion lifted their loved ones' moods. 'I don't think these actually improve cognition just by those interactions,' Dr Verghese said. 'But certainly improving quality of life and improving mood in patients with cognitive impairment is an important outcome in itself.' [ I am a university lecturer witnessing how AI is shrinking our ability to think Opens in new window ] AI companions could also be a boon for caregivers and families because they can serve as an extra set of eyes and ears, particularly for people living in specialist facilities for people with memory-related conditions such as dementia. We have to remember that this is a very vulnerable population One AI start-up, CloudMind, has been pilot testing its software, called BrightPath. The companion, via an app on a smartphone or tablet, chats with dementia patients about their favourite memories and hobbies – in one instance, a patient and the companion even sang together. In addition to facilitating conversation, BrightPath produces a daily summary of what the patient talked about and an assessment of the patient's mood. For the family, that can provide 'a peek of their loved one's life, even if they're apart,' said Monica Tsai, CloudMind's chief executive. The AI companion might also help nursing staff identify problems faster. If it hears certain key prompts, such as 'I'm thirsty' or 'I fell,' BrightPath is programmed to instruct the patient to ring their call button. While experts say there is real potential for AI to benefit adults with cognitive impairment, they also have some serious concerns. One is privacy. 'The more human-like the chatbot is, the more you're disclosing various information about yourself,' Dr De Freitas said. 'If this data is housed at a company, it could monetise that. It could also accidentally leak that information if it's hacked.' There is also a risk of further isolation if families or care-home staff use the technology as a replacement for human interaction, rather than as an add-on. 'That would be tragic,' Dr Verghese said. [ Exercise and socialising can help people at risk of dementia, large-scale study finds Opens in new window ] In addition, AI chatbots are known to make things up and take conversations down dark and disturbing paths, which could be especially confusing and distressing for a person with dementia. Dr Parviz and Dr Tsai both acknowledged such hallucinations as a potential issue and said they had programmed 'guard rails' into their AI software to prevent them from happening. But neither specified how that might work. 'We have to remember that this is a very vulnerable population,' Dr De Freitas said, adding: 'We need to think about having additional protections.' - This article originally appeared in the New York Times


Irish Times
07-08-2025
- Irish Times
Eli Lilly obesity pill disappoints in trial, sending shares down 14%
Eli Lilly 's potential obesity pill helped patients lose less weight than investors had hoped during a trial, sending shares in the drugmaker down more than 14 per cent in early trading. The pharmaceutical group said on Thursday that patients taking orforglipron lost an average of 12.4 per cent of their body weight, at the lower end of the market's expectations for the closely watched medicine. Trial participants taking a placebo lost 0.9 per cent. A pill is expected to offer less dramatic weight loss than injectables, where Lilly's Zepbound currently offers the most weight loss at an average of 23 per cent. Evan Seigerman, an analyst at BMO Capital markets, said investors had been hoping for a minimum weight loss of about 13.7 per cent of body weight. Novo Nordisk 's oral weight loss drug, which has been submitted for approval in the US, helped trial participants lose about 15 per cent of their body weight. Shares in Novo Nordisk, Lilly's main rival in the obesity market, jumped as much as 14 per cent. Mr Seigerman also said the trial showed the rate of side effects when taking Lilly's pill – nausea, vomiting and diarrhoea – was slightly worse than expected. The trial result was announced as Lilly reported its second-quarter results, beating analysts' expectations, and raised the midpoint of its guidance for the full year. David Ricks, Lilly's chief executive, said it was 'another quarter of strong performance'. The pharmaceutical industry is under pressure from the Trump administration to lower prices voluntarily, or face a 'Most Favoured Nation' drug pricing policy that would peg US drug prices to the lower prices in other developed nations. Mr Ricks warned against importing 'foreign pricing controls', arguing it would harm patients and US competitiveness. The company reported revenues of $15.6 billion (€13.4 billion) in the three months to June, up 38 per cent on the same period last year. Sales of Zepbound, prescribed for obesity, soared by 172 per cent, and Mounjaro, prescribed for diabetes, jumped 68 per cent. Lilly now expects full-year revenue between $60 billion to $62 billion, up from its previous range of $58 billion to $61 billion. The optimistic outlook contrasts sharply with rival Novo Nordisk, which lowered its forecasts for profit and sales growth last week, wiping €60 billion off its value. Novo Nordisk has been losing ground to Lilly in the US market, as well as facing competition from copycat versions of its weight loss and diabetes drugs. Investors had been excited that Lilly could dominate the market for oral weight loss drugs with orforglipron. While the trial result disappointed investors, the once-daily pill met the trial's goals, including showing it can have a positive impact on heart health, and Lilly said it was on track to submit the medicine to regulators for approval later this year. Just over 10 per cent of the high-dose patients dropped out of the Lilly trial due to adverse side effects, the company said. No liver safety issues were seen. In April, Lilly shares jumped almost 15 per cent when another trial, among diabetic patients, showed it could help them lose weight and lower their blood sugar. Daniel Skovronsky, Lilly's chief scientific officer, told analysts they should be wary of comparing trials over different time periods and in different populations. 'Wall Street is kind of focused on the exact numbers here, the cross trial comparisons, [but] I don't think that carries over to the real world,' he said. – Copyright The Financial Times Limited 2025